by San Rocco Therapeutics | Feb 5, 2026 | News
The Gene Therapy No One Is Talking About: San Rocco and the Cost of Silence in Sickle Cell Care As the biotech press dissects operational delays facing Vertex Pharmaceuticals’ CRISPR-based therapy for sickle cell disease, one gene therapy program has remained...
by Giancarlo Girondi | Jan 14, 2026 | News
From Bench to Bedside TrialSite News has spent years documenting a quieter but consequential counter-narrative in gene therapy—one that shifts attention away from prestige approvals and toward who actually gets cured. At the center of that story is San Rocco...
by San Rocco Therapeutics | Jan 9, 2026 | News
Researcher Pioneers Faster, Cheaper Gene Therapy for Hemoglobin Disorders For millions living with hemoglobin deficiencies such as sickle cell disease or beta thalassemia, every day is a battle against pain, costly treatments, and uncertainty. Dr. Frank Park is racing...
by Giancarlo Girondi | Dec 31, 2025 | News
The Cure Is Real. The Bottleneck Isn’t Scientific. So Why Is San Rocco Missing From the Story? Two years after the U.S. Food and Drug Administration (FDA) first approvals of gene therapies for sickle cell disease, the central question is no longer whether cures are...
by San Rocco Therapeutics | Nov 18, 2025 | News
San Rocco Therapeutics Salutes The Waltons In 1995, driven by love of their children, the Patrick Girondi and John Walton families united to fight life-threatening health conditions which afflicted their sons. Today, after 30 years, the collaboration promises...
by Giancarlo Girondi | Oct 24, 2025 | News
The Great Cell and Gene Therapy Reckoning: From Revolutionary Promise to Industry Crossroads Just days ago, on October 21, Belgian biotech Galapagos became the latest major casualty in what can only be described as a crisis of confidence sweeping through the cell and...
